Guger Technologies OG - mindBEAGLE: The First EEG-based BCI System Ever for Communication with Complete Locked-in Patients

Food and Healthcare Press Releases Tuesday June 13, 2017 09:01
GRAZ, Austria--13 Jun--PRNewswire/InfoQuest

Frontiers in Neuroscience recently published an article presenting mindBEAGLE as the very first and only EEG-based Brain-Computer Interface (BCI) that enables communication with patients who suffer from locked-in syndrome (LIS), complete locked-in syndrome (CLIS) or disorders of consciousness (DOC). It is widely known that these patients need BCIs that do not rely on visual stimuli and are easy to use. Paradigms based on non-visual evoked potentials and motor imagery can be effective for these patients. Therefore, mindBEAGLE has been developed and works with auditory, vibro-tactile (both based on P300) and motor-imagery paradigms in less than 20 minutes. In the study, 9 out of 12 LIS patients could communicate by using the vibro-tactile or motor-imagery paradigms. There were even 2 CLIS patients that could use the mindBEAGLE system to communicate. The results show that the system can restore communication to different patients.

(Photo: http://mma.prnewswire.com/media/521845/mindBEAGLE_Systemc.jpg )
(Photo: http://mma.prnewswire.com/media/521844/mindBEAGLE_Sujetc.jpg )

"The data reported in this paper were collected in a real world setting and demonstrate that the BCIs can revolutionize the management of several neurological disorders. Despite the substantial or complete loss of voluntary movements and speech, LIS and CLIS patients using this technology may continue to interact with the environment and participate in decisions. This achievement would represent a dramatic improvement of their quality of life." - Rossella Spataro, MD, Neurologist at the ALS Clinical Research Center, University of Palermo, Italy and co-author of this publication in the Journal of Neuroscience.

Watch the interview with Rossella Spataro and the daughter of a CLIS patient, who managed to talk to her mother with mindBEAGLE: https://www.youtube.com/watch?v=QSa3rRAT2ig&feature=youtu.be
Online Publication in Frontiers in Neuroscience: http://journal.frontiersin.org/article/10.3389/fnins.2017.00251/full
Sarah Breinbauer | Guger Technologies OG
Phone: +43 7251 222 40 | E-Mail: breinbauer@gtec.at
Press Kit: www.mindBEAGLE.at
Source: Guger Technologies OG

Latest Press Release

ESMO Emphasises Importance of Cancer on Global Health Agenda at WHA

At the World Health Assembly in Geneva, ESMO delivered two statements positioning cancer as a priority on the WHO global agenda. (Photo: https://mma.prnewswire.com/media/696385/WHA_Global_Health_Agenda.jpg ) ESMO advocated the strengthening of health...

Real-World Evidence Shows Clinically Meaningful Weight Loss in People Receiving Saxenda(R)

People treated with Saxenda(R) (liraglutide 3 mg) for weight management lost an average of 8.1 kg after six months in a real-world clinical setting, in combination with diet and exercise. The data were presented this week at both the 25th European...

Venus Medtech#s strategic investment in Keystone Heart deepens the technical layout of cerebral embolic protection market

China Venus Medtech (Hangzhou) Inc. announced a partnership agreement for strategic investment and authorization with Keystone Heart. This agreement will grant Venus Medtech the right to exclusively develop, manufacture and sell the 3rd generation...

WCG (WIRB-Copernicus Group) Clinical Services Division Opens Office in Japan

WCG(TM) (WIRB-Copernicus Group(R)) Clinical Services Division, the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the opening of the company's new office in Tokyo, Japan....

Head-to-Head Trial Shows Refixia(R) Achieves Greater Total Factor IX Exposure in People With Haemophilia B Than Recombinant Factor IX-Fc Fusion Protein

Adults with haemophilia B who received a single dose Refixia(R) (nonacog beta pegol; N9-GP) achieved greater total factor IX exposure than those treated with rFIXFc (recombinant factor IX-Fc fusion protein). The head-to-head paradigm7 trial also observed...

Related Topics